Additionally, as our TP53-loss phenocopy signature was trained on clinical samples across cancer types and validated in pan-cancer in vitro datasets for chemotherapy response, while our initial clinical validation focused on early-stage breast cancer, there is the potential for broader applicability across tumor types, though this would require additional clinical validation. This evidence concerns the gene TP53 and neoplasm.